(NASDAQ: ZVRA) Zevra Therapeutics's forecast annual revenue growth rate of 54.4% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.25%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.49%.
Zevra Therapeutics's revenue in 2025 is $62,020,000.On average, 3 Wall Street analysts forecast ZVRA's revenue for 2025 to be $5,514,149,989, with the lowest ZVRA revenue forecast at $5,332,833,645, and the highest ZVRA revenue forecast at $5,674,696,349. On average, 3 Wall Street analysts forecast ZVRA's revenue for 2026 to be $8,668,717,563, with the lowest ZVRA revenue forecast at $7,477,194,121, and the highest ZVRA revenue forecast at $9,587,873,543.
In 2027, ZVRA is forecast to generate $13,110,911,854 in revenue, with the lowest revenue forecast at $12,272,253,594 and the highest revenue forecast at $13,949,570,114.